

# Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE)

 [consortiapedia.fastercures.org/consortia/biomarcare/](http://consortiapedia.fastercures.org/consortia/biomarcare/)

## Research Areas



### Biomarker Research

Diagnostic

## At a Glance

- Status: **Active Consortium**
- Year Launched: **2011**
- Initiating Organization: **European Commission Seventh Framework Programme (FP7)**
- Initiator Type: **Government**
- Location: **Europe**

## Abstract

BiomarCaRE is a collaborative research project that integrates clinical, epidemiological, and biomarker research, as well as commercial enterprises throughout Europe, North America, and Australia. The BiomarCaRE project aims to determine the additional value of multiple (new) biomarkers to improve risk estimation of cardiovascular diseases (CVD)-related events in Europe. Ultimately, our BiomarCaRE consortium will develop a "European biomarker panel" for CVD prediction including the classical risk factors and established and novel biomarkers.

## Mission

Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions, and their role in the drive toward personalized medicine remain uncertain. Based on harmonized and standardized European population cohorts, BiomarCaRE has built significant research collaboration, expertise, and infrastructure in the European Union (EU). The consortium will apply

highly innovative SME-driven technologies and perform large-scale biomarker determination to assess the predictive value of existing and emerging biomarkers.

Selection of emerging biomarkers will be based on integrated cutting-edge quantitative proteomic, transcriptomic, metabolomic, and miRNomic datasets established by private and public consortium members that will be disclosed to this consortium. Existing biomarkers will be selected based on non-redundancy and their association with cardiovascular risk and phenotypes. After SME-guided development of innovative assay systems, biomarkers will be tested and validated in a step-wise fashion among European populations in primary and secondary prevention. In addition to their impact on risk prediction, their association with lifestyle determinants and cardiovascular phenotypes assessed by ultrasound and MRI technique will be evaluated.

A BiomarCaRE panel will be established, leading to improved disease prediction among different European populations. International collaborations with world-class clinical trial investigators will add data on the interaction of the BiomarCaRE panel with risk-lowering medication and lifestyle changes. The outcome of SME-driven technology development and clinical validation will undergo a medical technology assessment. The determination of cost-effectiveness will guide further clinical evaluation. These studies will reveal new methods of improved cardiovascular risk estimation and will open the path toward personalized medicine.

## Financing

---

It is a research project co-funded under the European Unions' Seventh Framework Programme.

Homepage

<http://www.biomarcare.eu/>

## Sponsors & Partners

---

University Medical Center Hamburg-Eppendorf

National Institute for Health and Welfare

Cavadis B.V.

Universitair Medisch Centrum

Helmholtz Zentrum Muenchen

Biocrates Life Sciences AG

University Lübeck  
University for Health Sciences, Medical Informatics and  
Technology  
Medizinische Hochschule Hannover  
Fleet Bioprocessing Ltd.  
Biocartis SA  
Research Network Services Ltd.  
Universitätsmedizin der Johannes Gutenberg-Universität  
Mainz  
University of Tromsø  
Università Cattolica del Sacro Cuore  
Ernst-Moritz-Arndt Universität Greifswald  
University College London  
The Queen's University of Belfast  
Institut Pasteur de Lille  
Catalan Institute of Cardiovascular Sciences  
Umeå Universitet  
Tartu University  
Research Centre for Prevention and Health  
University of Insubria  
University of Dundee  
Universitätsspital Basel  
Universitätsklinikum Ulm  
Hamilton Health Sciences Corporation  
University of Sydney  
Harvard Medical School, Brigham and Women's Hospital  
IRCCS Istituto Neurologico Mediterraneo

---

Updated: **04/22/2016**